Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 450

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 3
Chunk 450
---
 are qualifications, experience and skills for board members which
are important to our business:

·Leadership Experience – We seek directors
who demonstrate extraordinary leadership qualities. Strong leaders bring vision, diverse perspectives, and broad business insight to the
Company. They demonstrate practical management experience, skills for managing change, and knowledge of industries, geographies and risk
management strategies relevant to the Company;

·Finance Experience – We believe that all
directors should possess an understanding of finance and related reporting processes. We also seek directors who qualify as “audit
committee financial experts” as defined in rules of the SEC for service on the Audit Committee; and

·Industry Experience – We seek directors
who have relevant industry experience including: existing and new technologies, new or expanding businesses and a deep understanding of
the Company’s business environments.

The following biographical summaries set forth below
contain certain information concerning the members of our Board of Directors and our executive officers as of December 31, 2024, including
principal occupation, business experience, other directorships, and director qualifications. There is no blood or other familial relationship
between or among our directors or executive officers.

 39 

Steven King. Mr. King was nominated to serve
as a director on August 21, 2020 and was appointed President and Chief Executive Officer on August 31, 2020. Mr. King has served as President
and Chief Executive Officer of Peregrine Pharmaceuticals, Inc. (now known as Avid Bioservices, Inc.) (Nasdaq: CDMO) and its wholly owned
biomanufacturing subsidiary Avid Bioservices, Inc., for over 15 years, during which time the company advanced its lead compound through
Phase III clinical development, while growing revenues to over $55 million. Prior to joining Peregrine, Mr. King was employed at Vascular
Targeting Technologies, Inc., which was acquired by Peregrine in 1997. Mr. King served in a variety of executive roles at Peregrine and
Avid Bioservices, Inc., including Chief Executive Officer and board member of Peregrine (2003 to 2017), and President and board member
of Avid Bioservices (2002-2017). Mr. King also serves as a member of the board of directors of Oncotelic Therapeutics Inc.

The Board concluded that Mr. King should serve as
a director because of his extensive scientific understanding of technologies in development and expertise in developing and manufacturing
biotechnology products